Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Systemic Lupus Erythematosus (SLE)~Exclusion Criteria:~* Severe neuropsychiatric or severe renal Systemic Lupus Erythematosus (SLE)~* History of chronic, recurrent, or recent severe infection~* Significant hematologic abnormalities~* History of cancer, heart failure, renal disease, liver disease or other serious illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CDP7657 (Type: EXPERIMENTAL): CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).